These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6206307)

  • 1. Cardiovascular pharmacology of ACC-9089--a novel, ultra-short-acting, beta-adrenergic receptor antagonist.
    Gorczynski RJ; Vuong A
    J Cardiovasc Pharmacol; 1984; 6(4):555-64. PubMed ID: 6206307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of ASL-8052, a novel beta-adrenergic receptor antagonist with an ultrashort duration of action.
    Gorczynski RJ; Shaffer JE; Lee RJ
    J Cardiovasc Pharmacol; 1983; 5(4):668-77. PubMed ID: 6193366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenoceptor-blocking activity and cardiohemodynamic effects of carvedilol in animals.
    Kawada T; Ishibashi T; Nakazawa M; Satoh S; Imai S
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):147-53. PubMed ID: 1696657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and pharmacokinetics of esmolol.
    Reynolds RD; Gorczynski RJ; Quon CY
    J Clin Pharmacol; 1986 Mar; 26(S1):A3-A14. PubMed ID: 2870084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blocking and hemodynamic effects of ASL-8052.
    Gorczynski RJ; Murthy VS; Hwang TF
    J Cardiovasc Pharmacol; 1984; 6(6):1548-59. PubMed ID: 6084788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasomolol: an ultra short-acting and vasorelaxant vanilloid type beta 1-adrenoceptor antagonist.
    Lin YT; Wu BN; Wu JR; Lo YC; Chen LC; Chen IJ
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):149-57. PubMed ID: 8797149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines.
    Liang C; Doherty JU; Faillace R; Maekawa K; Arnold S; Gavras H; Hood WB
    J Clin Invest; 1982 Jun; 69(6):1321-36. PubMed ID: 6123523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atenolol, its cardioselective property for adrenergic beta-receptor blocking action and effect on the cardiac function (author's transl)].
    Kanno M; Nakaya H; Hattori Y; Izumi T; Nishimura T; Sakai K; Abiko Y
    Nihon Yakurigaku Zasshi; 1980 Oct; 76(7):621-32. PubMed ID: 6111522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectivity of the intrinsic sympathomimetic activity of the beta-adrenergic blocking drug bucindolol.
    Leff AR; Garrity ER; Munoz NM; Tallet J; Cavigelli M; Deitchman D; Rajfer SI
    J Cardiovasc Pharmacol; 1984; 6(5):859-66. PubMed ID: 6209492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flestolol: an ultra-short-acting beta-adrenergic blocking agent.
    Barton SD; Burge J; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A36-A39. PubMed ID: 2870085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-adrenoceptor antagonist activity of 3-methoxyisoprenaline.
    Bassett JR
    Br J Pharmacol; 1971 Jan; 41(1):113-21. PubMed ID: 4396127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.
    Farmer JB; Kennedy I; Levy GP; Marshall RJ
    Br J Pharmacol; 1972 Aug; 45(4):660-75. PubMed ID: 4404413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular pharmacology of ASL-8052, an ultra-short acting beta blocker.
    Murthy VS; Hwang TF; Zagar ME; Vollmer RR; Schmidt DH
    Eur J Pharmacol; 1983 Oct; 94(1-2):43-51. PubMed ID: 6140172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of propranolol on vascular responses to sympathetic nerve stimulation.
    Dawes PM; Faulkner DC
    Br J Pharmacol; 1975 Apr; 53(4):517-24. PubMed ID: 238703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.
    Lee RJ; Evans DB; Baky SH; Laffan RJ
    Eur J Pharmacol; 1975; 33(2):371-82. PubMed ID: 241655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity.
    Sheu MM; Wu BN; Ho WC; Hong SJ; Chen SJ; Lin YT; Chen IJ
    Pharmacology; 1997 Apr; 54(4):211-24. PubMed ID: 9211567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
    Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic activity of flestolol, a novel ultra-short-acting beta-adrenoceptor antagonist, in the dog.
    Reynolds RD; Brown BS
    Eur J Pharmacol; 1986 Nov; 131(1):55-66. PubMed ID: 2880726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.